Anti-Obesity Medications May Affect Survival in People with Knee or Hip Osteoarthritis

ReachMD Healthcare Image


Credit: Pixabay/CC0 Public Domain

New research published in Arthritis & Rheumatology suggests that for people overweight or with obesity who also have knee or hip osteoarthritis, a slow-to-moderate—but not fast—rate of weight loss caused by anti-obesity medications may lower their risk of premature death.

Among 6,524 participants with knee or hip osteoarthritis who were taking orlistat, sibutramine, or rimonabant, the five-year death rate was 5.3%, 4.0%, and 5.4% for the "weight gain/stable," "slow-to-moderate weight loss," and "fast weight loss" groups, respectively. Compared with the "weight gain/stable" group," the risk of death was 28% lower for the "slow-to-moderate weight loss" group and only 1% lower for the "fast weight loss" arm.

"A slow-to-moderate rate of weight loss induced by anti-obesity medications may lower the risk of death in overweight/obese people with knee/hip osteoarthritis," said first author Jie Wei, Ph.D., of Xiangya Hospital, Central South University, in China.

More information: Jie Wei et al, Weight Loss Induced by Antiobesity Medications and All‐Cause Mortality Among Patients With Knee or Hip Osteoarthritis, Arthritis & Rheumatology (2023). DOI: 10.1002/art.42754

Citation: Anti-obesity medications may affect survival in people with knee or hip osteoarthritis (2023, December 6) retrieved 6 December 2023 from

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Facebook Comments


We’re glad to see you’re enjoying Crohn's Colitis Professional…
but how about a more personalized experience?

Register for free